Biomarin (BMRN) just recently announced that the FDA has accepted for Priority Review the BLA for ValRox (valoctocogene roxaparvovec) for adults with hemophilia A, notes biotech expert John McCamant, editor of The Medical Technology Stock Letter.More from John McCamant:  Alkermes Targets Bipolar Disorder and Schizophrenia For the past 2+ years, we have known that the FDA has been proactive with gene therapy companies with an emphasis on hemophilia.